top of page

EMA Guidance: How to Fill the Application Form for Centralised Type IA and IB Variations

Writer's picture: Sharan MuruganSharan Murugan

Updated: Oct 17, 2022

Recently EMA released an updated guidance document for the purpose of simplifying the completion of the application form process for submitting type A and IB variations to the Centralised Procedure.

The General points that you need to consider when you are filling out the application form are:

  • It is important that the application form and cover letter are consistent.

  • Providing confusing or contradictory information can delay the procedure and must ensure that this is avoided.

  • In accordance with the Variations Guidelines, the changes in the section 'Precise scope' and the table 'Present and proposed' should be reflected under the Types of changes section, by their corresponding scope indent.

  • Product information - Do not submit Annex IV as part of the Product Information Annexes.

  • Make sure to include the filled and signed Product Information Annexes Checklist (europa.eu) when the affected type of PI is involved; without this checklist, supplementary information will be requested and the process could be delayed.

  • Consult the EMA/CMDh explanatory notes on the Variation Application Form for further assistance.

To facilitate the application review, the following documents should be attached to the Application form:

  1. Letter of Authorization or Power of Attorney

  2. Any Document that do not fit into eCTD but can facilitate validation

Click this LINK to know in detail How to Fill the Application Form for Centralised Type IA and IB Variations.


Also, there was a Regulatory and procedural guideline released for public consultation: Data Quality Framework for EU medicines regulation describes the general considerations on data quality relevant to regulatory decision-making, as well as the dimensions, subdimensions, characterizations, and metrics associated with them.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page